HIGHLIGHTS
- who: GBM et al. from the Department of and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER-Hajipur), Hajipur, India Al Jouf University, Saudi Arabia have published the Article: Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development, in the Journal: (JOURNAL)
- what: The aim of this study was to see how effective olaparib is in IDHmutant subjects with recurrent high-grade type gliomas based on their 6-month growth-free survival rate. This study examines the effectiveness of olaparib in treating cholangiocarcinoma, glioma, and solid . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.